| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nursing Homes | 50 | 2024 | 665 | 11.100 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 22 | 2024 | 151 | 5.180 |
Why?
|
| Antipsychotic Agents | 23 | 2024 | 312 | 4.740 |
Why?
|
| Aged | 207 | 2024 | 13341 | 4.580 |
Why?
|
| Homes for the Aged | 19 | 2024 | 164 | 4.480 |
Why?
|
| Heart Failure | 34 | 2023 | 867 | 4.090 |
Why?
|
| Anticoagulants | 23 | 2024 | 487 | 3.760 |
Why?
|
| Long-Term Care | 21 | 2021 | 174 | 3.660 |
Why?
|
| Dementia | 14 | 2024 | 247 | 3.480 |
Why?
|
| Medication Errors | 20 | 2023 | 116 | 3.460 |
Why?
|
| Aged, 80 and over | 114 | 2024 | 5089 | 3.350 |
Why?
|
| Geriatrics | 6 | 2024 | 41 | 3.300 |
Why?
|
| Inappropriate Prescribing | 13 | 2024 | 67 | 2.990 |
Why?
|
| Humans | 277 | 2024 | 59517 | 2.950 |
Why?
|
| Drug Prescriptions | 17 | 2021 | 188 | 2.880 |
Why?
|
| Polypharmacy | 14 | 2024 | 62 | 2.710 |
Why?
|
| Practice Patterns, Physicians' | 24 | 2024 | 715 | 2.490 |
Why?
|
| United States | 84 | 2024 | 7513 | 2.450 |
Why?
|
| Decision Support Systems, Clinical | 10 | 2011 | 71 | 2.450 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2019 | 212 | 2.390 |
Why?
|
| Male | 176 | 2024 | 27572 | 2.380 |
Why?
|
| Primary Prevention | 10 | 2019 | 137 | 2.370 |
Why?
|
| Patient Selection | 10 | 2021 | 446 | 2.360 |
Why?
|
| Pharmaceutical Preparations | 11 | 2021 | 122 | 2.350 |
Why?
|
| Female | 183 | 2024 | 30918 | 2.350 |
Why?
|
| Myocardial Infarction | 26 | 2021 | 864 | 2.240 |
Why?
|
| Activities of Daily Living | 6 | 2023 | 298 | 2.230 |
Why?
|
| Alzheimer Disease | 5 | 2024 | 551 | 2.200 |
Why?
|
| Hospitalization | 36 | 2022 | 1283 | 2.150 |
Why?
|
| Multiple Chronic Conditions | 6 | 2023 | 34 | 1.960 |
Why?
|
| Accidental Falls | 8 | 2021 | 145 | 1.920 |
Why?
|
| Atrial Fibrillation | 16 | 2024 | 798 | 1.910 |
Why?
|
| Clinical Trials as Topic | 6 | 2022 | 442 | 1.910 |
Why?
|
| Medical Order Entry Systems | 8 | 2011 | 45 | 1.860 |
Why?
|
| Warfarin | 8 | 2018 | 109 | 1.740 |
Why?
|
| Drug Monitoring | 13 | 2014 | 99 | 1.660 |
Why?
|
| Drug Utilization | 18 | 2020 | 223 | 1.660 |
Why?
|
| Pharmacists | 3 | 2023 | 123 | 1.640 |
Why?
|
| Algorithms | 8 | 2021 | 990 | 1.580 |
Why?
|
| Chronic Disease | 11 | 2023 | 735 | 1.530 |
Why?
|
| Medicare | 12 | 2023 | 601 | 1.510 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2024 | 669 | 1.500 |
Why?
|
| Patient Discharge | 11 | 2019 | 479 | 1.490 |
Why?
|
| Health Maintenance Organizations | 17 | 2009 | 87 | 1.480 |
Why?
|
| Cohort Studies | 29 | 2023 | 2442 | 1.440 |
Why?
|
| Research Design | 9 | 2023 | 566 | 1.430 |
Why?
|
| Medicare Part D | 9 | 2021 | 35 | 1.370 |
Why?
|
| Cardiovascular Diseases | 9 | 2017 | 827 | 1.350 |
Why?
|
| Continuity of Patient Care | 4 | 2017 | 172 | 1.310 |
Why?
|
| Retrospective Studies | 54 | 2023 | 6009 | 1.310 |
Why?
|
| Middle Aged | 90 | 2024 | 16276 | 1.300 |
Why?
|
| Electronic Health Records | 6 | 2023 | 352 | 1.290 |
Why?
|
| Databases, Factual | 12 | 2024 | 838 | 1.280 |
Why?
|
| Risk Factors | 51 | 2022 | 5016 | 1.280 |
Why?
|
| Potentially Inappropriate Medication List | 3 | 2024 | 14 | 1.280 |
Why?
|
| Hip Fractures | 6 | 2018 | 79 | 1.250 |
Why?
|
| Marketing | 3 | 2018 | 18 | 1.250 |
Why?
|
| Stroke Volume | 9 | 2016 | 318 | 1.230 |
Why?
|
| Medication Systems | 5 | 2021 | 18 | 1.220 |
Why?
|
| Independent Living | 7 | 2022 | 45 | 1.180 |
Why?
|
| Patient Readmission | 9 | 2021 | 420 | 1.180 |
Why?
|
| Safety Management | 5 | 2012 | 143 | 1.170 |
Why?
|
| Ambulatory Care | 7 | 2023 | 300 | 1.130 |
Why?
|
| Risk Assessment | 27 | 2022 | 1915 | 1.120 |
Why?
|
| Decision Making | 4 | 2018 | 390 | 1.090 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2018 | 114 | 1.070 |
Why?
|
| Quality Assurance, Health Care | 5 | 2011 | 246 | 1.060 |
Why?
|
| Primary Health Care | 6 | 2020 | 647 | 1.050 |
Why?
|
| Atherosclerosis | 2 | 2018 | 147 | 1.050 |
Why?
|
| Drug Industry | 4 | 2018 | 40 | 1.040 |
Why?
|
| Quality of Health Care | 12 | 2016 | 519 | 1.040 |
Why?
|
| Health Services Needs and Demand | 2 | 2021 | 214 | 1.040 |
Why?
|
| Deprescriptions | 2 | 2024 | 22 | 0.970 |
Why?
|
| Stroke | 12 | 2022 | 1138 | 0.960 |
Why?
|
| Drug Labeling | 5 | 2013 | 27 | 0.940 |
Why?
|
| Body Mass Index | 2 | 2019 | 886 | 0.940 |
Why?
|
| Truth Disclosure | 4 | 2006 | 54 | 0.940 |
Why?
|
| Pandemics | 5 | 2022 | 608 | 0.940 |
Why?
|
| Diabetes Mellitus | 3 | 2022 | 537 | 0.930 |
Why?
|
| Medical Errors | 5 | 2009 | 193 | 0.900 |
Why?
|
| Drug Therapy, Computer-Assisted | 3 | 2009 | 10 | 0.900 |
Why?
|
| Family | 2 | 2016 | 220 | 0.890 |
Why?
|
| Evidence-Based Medicine | 5 | 2016 | 452 | 0.880 |
Why?
|
| Endpoint Determination | 2 | 2014 | 24 | 0.880 |
Why?
|
| Students, Medical | 2 | 2023 | 243 | 0.870 |
Why?
|
| Physician-Patient Relations | 6 | 2008 | 388 | 0.870 |
Why?
|
| Delivery of Health Care | 4 | 2022 | 421 | 0.860 |
Why?
|
| Cost-Benefit Analysis | 3 | 2021 | 299 | 0.850 |
Why?
|
| Education, Medical, Undergraduate | 3 | 2015 | 146 | 0.830 |
Why?
|
| Defibrillators, Implantable | 8 | 2019 | 258 | 0.820 |
Why?
|
| Ventricular Function, Left | 8 | 2018 | 263 | 0.810 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 9 | 2011 | 51 | 0.800 |
Why?
|
| Career Choice | 1 | 2023 | 110 | 0.800 |
Why?
|
| Frail Elderly | 3 | 2022 | 110 | 0.780 |
Why?
|
| Validation Studies as Topic | 2 | 2012 | 22 | 0.780 |
Why?
|
| Drug Costs | 9 | 2021 | 59 | 0.780 |
Why?
|
| Aging | 6 | 2022 | 723 | 0.780 |
Why?
|
| Severity of Illness Index | 8 | 2020 | 1449 | 0.770 |
Why?
|
| Surveys and Questionnaires | 17 | 2024 | 2592 | 0.770 |
Why?
|
| Prospective Studies | 15 | 2024 | 3101 | 0.760 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2019 | 160 | 0.750 |
Why?
|
| Disabled Persons | 6 | 2021 | 205 | 0.750 |
Why?
|
| Demography | 3 | 2020 | 178 | 0.750 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2022 | 142 | 0.740 |
Why?
|
| Antiparkinson Agents | 1 | 2021 | 9 | 0.730 |
Why?
|
| Dopamine Antagonists | 1 | 2021 | 15 | 0.730 |
Why?
|
| Sex Factors | 18 | 2024 | 960 | 0.730 |
Why?
|
| Drug Therapy | 7 | 2008 | 61 | 0.730 |
Why?
|
| Skilled Nursing Facilities | 2 | 2019 | 84 | 0.720 |
Why?
|
| Massachusetts | 22 | 2021 | 2089 | 0.720 |
Why?
|
| Medical Records Systems, Computerized | 6 | 2009 | 66 | 0.710 |
Why?
|
| Benzoxazoles | 1 | 2020 | 6 | 0.710 |
Why?
|
| Cognitive Dysfunction | 5 | 2024 | 262 | 0.700 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 330 | 0.700 |
Why?
|
| Subacute Care | 1 | 2020 | 9 | 0.700 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2020 | 17 | 0.690 |
Why?
|
| Obesity | 4 | 2023 | 1186 | 0.690 |
Why?
|
| Patient Participation | 2 | 2020 | 211 | 0.670 |
Why?
|
| Biomedical Research | 2 | 2021 | 250 | 0.670 |
Why?
|
| Age Factors | 24 | 2024 | 1518 | 0.660 |
Why?
|
| Hypertension | 3 | 2023 | 601 | 0.650 |
Why?
|
| Communication | 5 | 2011 | 554 | 0.640 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2017 | 149 | 0.640 |
Why?
|
| Geriatric Assessment | 8 | 2024 | 161 | 0.640 |
Why?
|
| Computer Simulation | 1 | 2021 | 455 | 0.630 |
Why?
|
| Nocturia | 1 | 2018 | 1 | 0.630 |
Why?
|
| Medical Informatics | 2 | 2016 | 68 | 0.630 |
Why?
|
| Reimbursement, Incentive | 2 | 2009 | 28 | 0.620 |
Why?
|
| Prevalence | 15 | 2021 | 1281 | 0.610 |
Why?
|
| Multimorbidity | 5 | 2023 | 38 | 0.610 |
Why?
|
| Renal Insufficiency | 2 | 2009 | 62 | 0.610 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2022 | 63 | 0.600 |
Why?
|
| Health Personnel | 2 | 2015 | 341 | 0.600 |
Why?
|
| Diuretics | 4 | 2023 | 58 | 0.600 |
Why?
|
| Prescription Drugs | 6 | 2014 | 50 | 0.600 |
Why?
|
| Medication Adherence | 8 | 2022 | 255 | 0.600 |
Why?
|
| Incidence | 17 | 2020 | 1237 | 0.590 |
Why?
|
| Adult | 37 | 2024 | 15787 | 0.590 |
Why?
|
| Treatment Outcome | 27 | 2021 | 5183 | 0.580 |
Why?
|
| Prescription Drug Overuse | 1 | 2017 | 7 | 0.580 |
Why?
|
| Practice Guidelines as Topic | 4 | 2016 | 703 | 0.580 |
Why?
|
| Research | 2 | 2017 | 191 | 0.570 |
Why?
|
| United States Food and Drug Administration | 7 | 2014 | 95 | 0.570 |
Why?
|
| Office Visits | 2 | 2014 | 41 | 0.570 |
Why?
|
| Government Regulation | 2 | 2017 | 44 | 0.570 |
Why?
|
| Time Factors | 25 | 2021 | 3579 | 0.560 |
Why?
|
| Urinary Catheters | 1 | 2016 | 4 | 0.550 |
Why?
|
| Urethral Obstruction | 1 | 2016 | 4 | 0.550 |
Why?
|
| Cross-Sectional Studies | 17 | 2024 | 2470 | 0.550 |
Why?
|
| Drug Utilization Review | 5 | 2016 | 56 | 0.550 |
Why?
|
| Death, Sudden, Cardiac | 6 | 2019 | 354 | 0.540 |
Why?
|
| Urinary Catheterization | 1 | 2016 | 19 | 0.540 |
Why?
|
| Ontario | 10 | 2023 | 43 | 0.540 |
Why?
|
| Frailty | 4 | 2024 | 125 | 0.540 |
Why?
|
| Societies, Medical | 1 | 2018 | 330 | 0.530 |
Why?
|
| Self Report | 2 | 2022 | 366 | 0.530 |
Why?
|
| Urinary Retention | 1 | 2016 | 30 | 0.530 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 56 | 0.520 |
Why?
|
| Lung Diseases | 1 | 2017 | 164 | 0.510 |
Why?
|
| Comorbidity | 10 | 2022 | 1091 | 0.510 |
Why?
|
| Professional-Family Relations | 1 | 2016 | 87 | 0.510 |
Why?
|
| Proportional Hazards Models | 13 | 2018 | 673 | 0.490 |
Why?
|
| Caregivers | 4 | 2024 | 216 | 0.490 |
Why?
|
| Rationalization | 1 | 2015 | 4 | 0.490 |
Why?
|
| Clinical Clerkship | 1 | 2015 | 83 | 0.490 |
Why?
|
| Guideline Adherence | 6 | 2013 | 296 | 0.480 |
Why?
|
| Arthritis, Rheumatoid | 4 | 2013 | 325 | 0.480 |
Why?
|
| Patient Satisfaction | 5 | 2022 | 410 | 0.470 |
Why?
|
| International Classification of Diseases | 5 | 2021 | 143 | 0.460 |
Why?
|
| Medication Therapy Management | 2 | 2017 | 25 | 0.460 |
Why?
|
| Reminder Systems | 3 | 2017 | 72 | 0.460 |
Why?
|
| Anemia | 3 | 2020 | 117 | 0.460 |
Why?
|
| Connecticut | 6 | 2015 | 86 | 0.460 |
Why?
|
| Follow-Up Studies | 14 | 2019 | 2329 | 0.460 |
Why?
|
| Benzodiazepines | 3 | 2010 | 98 | 0.450 |
Why?
|
| Chi-Square Distribution | 10 | 2017 | 403 | 0.450 |
Why?
|
| Postoperative Complications | 2 | 2017 | 1134 | 0.450 |
Why?
|
| Osteoarthritis | 2 | 2008 | 129 | 0.450 |
Why?
|
| Confidence Intervals | 9 | 2014 | 256 | 0.450 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2018 | 45 | 0.440 |
Why?
|
| Hemorrhage | 8 | 2022 | 277 | 0.440 |
Why?
|
| Consumer Product Safety | 1 | 2013 | 14 | 0.440 |
Why?
|
| Drug Approval | 1 | 2013 | 27 | 0.430 |
Why?
|
| Patient Education as Topic | 3 | 2024 | 446 | 0.430 |
Why?
|
| Treatment Refusal | 6 | 2008 | 60 | 0.430 |
Why?
|
| Managed Care Programs | 2 | 2005 | 93 | 0.430 |
Why?
|
| Calcium Channel Blockers | 3 | 2023 | 56 | 0.430 |
Why?
|
| Decision Support Techniques | 2 | 2020 | 180 | 0.420 |
Why?
|
| Odds Ratio | 12 | 2017 | 773 | 0.420 |
Why?
|
| Neoplasms | 3 | 2015 | 1243 | 0.420 |
Why?
|
| Digestive System Diseases | 1 | 2013 | 15 | 0.420 |
Why?
|
| Administration, Oral | 3 | 2023 | 344 | 0.420 |
Why?
|
| Resource Allocation | 1 | 2012 | 20 | 0.410 |
Why?
|
| Health Care Rationing | 1 | 2012 | 21 | 0.410 |
Why?
|
| Ischemic Attack, Transient | 2 | 2019 | 90 | 0.400 |
Why?
|
| Social Justice | 1 | 2012 | 30 | 0.400 |
Why?
|
| Emergencies | 1 | 2013 | 114 | 0.400 |
Why?
|
| Ambulatory Care Information Systems | 1 | 2012 | 8 | 0.400 |
Why?
|
| Life Expectancy | 1 | 2012 | 34 | 0.400 |
Why?
|
| Predictive Value of Tests | 8 | 2012 | 1032 | 0.390 |
Why?
|
| Iatrogenic Disease | 1 | 2012 | 57 | 0.390 |
Why?
|
| Multivariate Analysis | 11 | 2017 | 926 | 0.390 |
Why?
|
| Coronary Disease | 2 | 2011 | 250 | 0.380 |
Why?
|
| Fractures, Bone | 2 | 2022 | 139 | 0.380 |
Why?
|
| Population Surveillance | 5 | 2017 | 205 | 0.380 |
Why?
|
| Guidelines as Topic | 2 | 2010 | 158 | 0.380 |
Why?
|
| Drug Interactions | 6 | 2017 | 115 | 0.370 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 23 | 0.370 |
Why?
|
| Ambulatory Care Facilities | 3 | 2012 | 102 | 0.370 |
Why?
|
| Patients | 2 | 2020 | 102 | 0.370 |
Why?
|
| Home Nursing | 1 | 2011 | 21 | 0.370 |
Why?
|
| Electric Countershock | 3 | 2018 | 98 | 0.370 |
Why?
|
| Women | 1 | 2011 | 46 | 0.360 |
Why?
|
| Length of Stay | 7 | 2017 | 771 | 0.360 |
Why?
|
| Legislation, Drug | 4 | 2017 | 18 | 0.360 |
Why?
|
| Hospitals | 2 | 2012 | 376 | 0.350 |
Why?
|
| Health Expenditures | 4 | 2021 | 115 | 0.340 |
Why?
|
| New England | 8 | 2014 | 268 | 0.340 |
Why?
|
| Attitude of Health Personnel | 5 | 2024 | 559 | 0.340 |
Why?
|
| Mobility Limitation | 2 | 2020 | 49 | 0.340 |
Why?
|
| Clinical Protocols | 1 | 2011 | 134 | 0.340 |
Why?
|
| Hyperkalemia | 3 | 2022 | 23 | 0.340 |
Why?
|
| Acute Coronary Syndrome | 3 | 2017 | 258 | 0.330 |
Why?
|
| Physician-Nurse Relations | 1 | 2009 | 26 | 0.330 |
Why?
|
| Cognitive Dissonance | 1 | 2009 | 3 | 0.330 |
Why?
|
| Psychotropic Drugs | 1 | 2010 | 83 | 0.330 |
Why?
|
| Patient Compliance | 2 | 2012 | 372 | 0.330 |
Why?
|
| Self Care | 2 | 2009 | 211 | 0.320 |
Why?
|
| Electronic Prescribing | 1 | 2009 | 11 | 0.320 |
Why?
|
| Communication Barriers | 1 | 2009 | 59 | 0.320 |
Why?
|
| Ethics, Medical | 1 | 2009 | 38 | 0.320 |
Why?
|
| Conflict of Interest | 1 | 2009 | 35 | 0.320 |
Why?
|
| Survivors | 3 | 2017 | 148 | 0.320 |
Why?
|
| Abbreviations as Topic | 1 | 2008 | 3 | 0.320 |
Why?
|
| Regression Analysis | 4 | 2016 | 484 | 0.310 |
Why?
|
| Insurance, Pharmaceutical Services | 4 | 2013 | 24 | 0.310 |
Why?
|
| Cognition Disorders | 3 | 2017 | 218 | 0.310 |
Why?
|
| Patient Care Management | 2 | 2020 | 29 | 0.300 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2008 | 13 | 0.300 |
Why?
|
| Fees, Pharmaceutical | 2 | 2011 | 6 | 0.290 |
Why?
|
| Physicians | 3 | 2018 | 436 | 0.290 |
Why?
|
| Health Care Surveys | 5 | 2012 | 279 | 0.290 |
Why?
|
| Quality of Life | 5 | 2022 | 1117 | 0.290 |
Why?
|
| Assisted Living Facilities | 1 | 2007 | 10 | 0.290 |
Why?
|
| Videotape Recording | 1 | 2007 | 46 | 0.290 |
Why?
|
| Health Services | 2 | 2005 | 85 | 0.290 |
Why?
|
| Financing, Personal | 4 | 2011 | 25 | 0.290 |
Why?
|
| Longitudinal Studies | 9 | 2024 | 1225 | 0.290 |
Why?
|
| Drug Evaluation | 2 | 2007 | 20 | 0.290 |
Why?
|
| Narration | 1 | 2007 | 44 | 0.280 |
Why?
|
| Software | 4 | 2014 | 367 | 0.280 |
Why?
|
| Attitude to Health | 2 | 2006 | 275 | 0.280 |
Why?
|
| Acute Kidney Injury | 2 | 2022 | 131 | 0.280 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2018 | 142 | 0.280 |
Why?
|
| Hypoglycemic Agents | 2 | 2006 | 212 | 0.280 |
Why?
|
| Prescription Fees | 3 | 2014 | 6 | 0.270 |
Why?
|
| Health Services for the Aged | 2 | 2008 | 48 | 0.270 |
Why?
|
| Awards and Prizes | 1 | 2006 | 30 | 0.270 |
Why?
|
| Health Care Costs | 2 | 2005 | 204 | 0.270 |
Why?
|
| International Normalized Ratio | 3 | 2012 | 34 | 0.270 |
Why?
|
| Tibial Arteries | 1 | 2006 | 1 | 0.260 |
Why?
|
| Antirheumatic Agents | 3 | 2013 | 213 | 0.260 |
Why?
|
| Poisson Distribution | 3 | 2012 | 51 | 0.260 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2005 | 1 | 0.260 |
Why?
|
| Correspondence as Topic | 1 | 2005 | 11 | 0.260 |
Why?
|
| Community Health Services | 2 | 2008 | 128 | 0.250 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2006 | 68 | 0.250 |
Why?
|
| Disability Evaluation | 2 | 2017 | 216 | 0.250 |
Why?
|
| Logistic Models | 10 | 2017 | 1252 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 741 | 0.250 |
Why?
|
| Adolescent | 10 | 2017 | 5932 | 0.250 |
Why?
|
| Age Distribution | 5 | 2008 | 261 | 0.250 |
Why?
|
| Mandatory Programs | 1 | 2005 | 19 | 0.250 |
Why?
|
| Physicians, Primary Care | 2 | 2017 | 72 | 0.250 |
Why?
|
| Mental Disorders | 1 | 2013 | 766 | 0.250 |
Why?
|
| Population Dynamics | 1 | 2005 | 18 | 0.240 |
Why?
|
| Inpatients | 2 | 2019 | 296 | 0.240 |
Why?
|
| Residential Facilities | 1 | 2004 | 18 | 0.240 |
Why?
|
| Cholinergic Antagonists | 1 | 2024 | 30 | 0.240 |
Why?
|
| Thrombolytic Therapy | 3 | 2003 | 181 | 0.240 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 71 | 0.230 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2004 | 21 | 0.230 |
Why?
|
| Focus Groups | 2 | 2020 | 292 | 0.230 |
Why?
|
| Quality Improvement | 2 | 2021 | 425 | 0.230 |
Why?
|
| Health Services Research | 4 | 2017 | 270 | 0.230 |
Why?
|
| Young Adult | 7 | 2017 | 4331 | 0.230 |
Why?
|
| Off-Label Use | 2 | 2015 | 15 | 0.230 |
Why?
|
| Professional Role | 1 | 2024 | 37 | 0.220 |
Why?
|
| Diphosphonates | 1 | 2003 | 35 | 0.220 |
Why?
|
| Calcitonin | 1 | 2003 | 17 | 0.220 |
Why?
|
| Child | 7 | 2011 | 4306 | 0.220 |
Why?
|
| Morbidity | 2 | 2020 | 109 | 0.220 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2003 | 59 | 0.210 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2003 | 86 | 0.210 |
Why?
|
| Group Practice | 1 | 2003 | 12 | 0.210 |
Why?
|
| Statistics as Topic | 2 | 2014 | 147 | 0.210 |
Why?
|
| Risk | 3 | 2016 | 372 | 0.210 |
Why?
|
| Patient Care Team | 2 | 2002 | 327 | 0.210 |
Why?
|
| User-Computer Interface | 3 | 2009 | 129 | 0.210 |
Why?
|
| Interviews as Topic | 3 | 2016 | 486 | 0.200 |
Why?
|
| Data Collection | 4 | 2014 | 384 | 0.200 |
Why?
|
| Information Dissemination | 2 | 2015 | 117 | 0.200 |
Why?
|
| Prognosis | 9 | 2022 | 1572 | 0.200 |
Why?
|
| Review Literature as Topic | 1 | 2002 | 33 | 0.200 |
Why?
|
| Models, Educational | 1 | 2002 | 63 | 0.200 |
Why?
|
| Nursing Staff | 2 | 2013 | 41 | 0.200 |
Why?
|
| Paraproteinemias | 1 | 2022 | 18 | 0.200 |
Why?
|
| Bias | 1 | 2002 | 106 | 0.200 |
Why?
|
| Social Norms | 1 | 2021 | 9 | 0.190 |
Why?
|
| Insurance, Health | 4 | 2009 | 141 | 0.190 |
Why?
|
| Pilot Projects | 4 | 2015 | 919 | 0.190 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2022 | 33 | 0.190 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2021 | 61 | 0.190 |
Why?
|
| Edema | 1 | 2021 | 40 | 0.190 |
Why?
|
| Socioeconomic Factors | 9 | 2017 | 781 | 0.190 |
Why?
|
| Publishing | 1 | 2002 | 90 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 446 | 0.180 |
Why?
|
| Patient Transfer | 1 | 2002 | 93 | 0.180 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2021 | 51 | 0.180 |
Why?
|
| Weight Loss | 1 | 2023 | 260 | 0.180 |
Why?
|
| Survival Rate | 7 | 2019 | 791 | 0.180 |
Why?
|
| Patient Safety | 2 | 2014 | 243 | 0.180 |
Why?
|
| Pharmacy | 1 | 2021 | 18 | 0.180 |
Why?
|
| Cardiac Catheterization | 3 | 2015 | 250 | 0.180 |
Why?
|
| Sex Distribution | 4 | 2005 | 254 | 0.180 |
Why?
|
| Eligibility Determination | 1 | 2020 | 34 | 0.180 |
Why?
|
| Cause of Death | 4 | 2019 | 200 | 0.170 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2020 | 21 | 0.170 |
Why?
|
| Health Services Accessibility | 3 | 2012 | 542 | 0.170 |
Why?
|
| Low Back Pain | 1 | 2021 | 120 | 0.170 |
Why?
|
| Registries | 3 | 2017 | 803 | 0.170 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1063 | 0.170 |
Why?
|
| Empathy | 1 | 2020 | 65 | 0.170 |
Why?
|
| Venous Thromboembolism | 2 | 2014 | 140 | 0.170 |
Why?
|
| Medical Indigency | 3 | 2008 | 6 | 0.170 |
Why?
|
| Nurse's Role | 1 | 2020 | 121 | 0.170 |
Why?
|
| Periodicals as Topic | 1 | 2002 | 173 | 0.170 |
Why?
|
| Sample Size | 2 | 2023 | 59 | 0.170 |
Why?
|
| Emergency Medical Services | 2 | 2016 | 249 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 674 | 0.160 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 319 | 0.160 |
Why?
|
| Chest Pain | 1 | 2020 | 85 | 0.160 |
Why?
|
| Observation | 1 | 2019 | 30 | 0.160 |
Why?
|
| Antidiuretic Agents | 1 | 2018 | 2 | 0.160 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2018 | 3 | 0.160 |
Why?
|
| Disease Management | 2 | 2019 | 220 | 0.160 |
Why?
|
| Internationality | 1 | 2018 | 42 | 0.160 |
Why?
|
| Anti-Anxiety Agents | 2 | 2010 | 31 | 0.160 |
Why?
|
| Anxiety | 2 | 2020 | 395 | 0.160 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2009 | 24 | 0.150 |
Why?
|
| Delirium | 2 | 2016 | 56 | 0.150 |
Why?
|
| Thinness | 1 | 2018 | 39 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 4 | 2012 | 196 | 0.150 |
Why?
|
| Health Facility Size | 2 | 2015 | 17 | 0.150 |
Why?
|
| Child, Preschool | 4 | 2011 | 1839 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 160 | 0.150 |
Why?
|
| Cognition | 2 | 2022 | 459 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2019 | 153 | 0.150 |
Why?
|
| Education | 1 | 2018 | 74 | 0.150 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 328 | 0.150 |
Why?
|
| Cardiovascular Agents | 2 | 2011 | 100 | 0.150 |
Why?
|
| Pneumonia, Aspiration | 1 | 2017 | 17 | 0.150 |
Why?
|
| Sensitivity and Specificity | 4 | 2012 | 1095 | 0.150 |
Why?
|
| Outpatients | 2 | 2017 | 131 | 0.150 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 1129 | 0.150 |
Why?
|
| Thromboembolism | 1 | 2018 | 70 | 0.150 |
Why?
|
| Prescriptions | 1 | 2017 | 33 | 0.150 |
Why?
|
| Cost of Illness | 2 | 2010 | 155 | 0.150 |
Why?
|
| Propensity Score | 2 | 2015 | 134 | 0.140 |
Why?
|
| Organizational Innovation | 2 | 2008 | 85 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 187 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 322 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 199 | 0.140 |
Why?
|
| Kidney | 2 | 2016 | 395 | 0.140 |
Why?
|
| Third-Party Consent | 1 | 2016 | 9 | 0.140 |
Why?
|
| Behavioral Risk Factor Surveillance System | 2 | 2008 | 48 | 0.140 |
Why?
|
| Behavior Control | 1 | 2016 | 15 | 0.140 |
Why?
|
| Insurance Claim Review | 3 | 2012 | 80 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2017 | 161 | 0.130 |
Why?
|
| Diagnostic Errors | 1 | 2017 | 98 | 0.130 |
Why?
|
| Oxycodone | 1 | 2016 | 32 | 0.130 |
Why?
|
| Catheters, Indwelling | 1 | 2016 | 63 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2017 | 225 | 0.130 |
Why?
|
| Morphine | 1 | 2016 | 52 | 0.130 |
Why?
|
| Overweight | 1 | 2018 | 247 | 0.130 |
Why?
|
| Device Removal | 1 | 2016 | 58 | 0.130 |
Why?
|
| Psychosocial Deprivation | 1 | 2015 | 7 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 809 | 0.130 |
Why?
|
| Depression | 3 | 2020 | 857 | 0.130 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 43 | 0.130 |
Why?
|
| Residence Characteristics | 3 | 2008 | 224 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 55 | 0.130 |
Why?
|
| Hospice Care | 1 | 2016 | 59 | 0.130 |
Why?
|
| Fentanyl | 1 | 2016 | 70 | 0.130 |
Why?
|
| Urinary Tract Infections | 1 | 2016 | 76 | 0.130 |
Why?
|
| Transitional Care | 1 | 2015 | 26 | 0.130 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 237 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2016 | 176 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2012 | 1551 | 0.120 |
Why?
|
| Nausea | 1 | 2016 | 109 | 0.120 |
Why?
|
| Goals | 1 | 2015 | 89 | 0.120 |
Why?
|
| Cross Infection | 1 | 2016 | 151 | 0.120 |
Why?
|
| Surgical Procedures, Operative | 1 | 2016 | 139 | 0.120 |
Why?
|
| Marketing of Health Services | 1 | 2015 | 23 | 0.120 |
Why?
|
| Clinical Competence | 2 | 2024 | 678 | 0.120 |
Why?
|
| Heart Function Tests | 1 | 2014 | 14 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2014 | 45 | 0.120 |
Why?
|
| Organizational Culture | 2 | 2012 | 112 | 0.120 |
Why?
|
| Pediatrics | 2 | 2008 | 266 | 0.120 |
Why?
|
| Urban Population | 1 | 2015 | 182 | 0.110 |
Why?
|
| Consultants | 1 | 2014 | 12 | 0.110 |
Why?
|
| Executive Function | 1 | 2014 | 62 | 0.110 |
Why?
|
| Hospital Mortality | 4 | 2016 | 846 | 0.110 |
Why?
|
| Chronic Pain | 1 | 2016 | 142 | 0.110 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2013 | 11 | 0.110 |
Why?
|
| Contraindications | 2 | 2005 | 45 | 0.110 |
Why?
|
| Medical Staff | 1 | 2013 | 14 | 0.110 |
Why?
|
| Psychomotor Performance | 1 | 2014 | 133 | 0.110 |
Why?
|
| Georgia | 3 | 2019 | 88 | 0.110 |
Why?
|
| Administrative Personnel | 1 | 2013 | 33 | 0.110 |
Why?
|
| Deductibles and Coinsurance | 2 | 2010 | 8 | 0.110 |
Why?
|
| Pain Management | 1 | 2015 | 145 | 0.110 |
Why?
|
| History, Ancient | 1 | 2013 | 11 | 0.110 |
Why?
|
| Insurance Coverage | 2 | 2011 | 98 | 0.110 |
Why?
|
| Cardiotonic Agents | 1 | 2013 | 48 | 0.100 |
Why?
|
| Pharmacies | 1 | 2013 | 36 | 0.100 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2015 | 169 | 0.100 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2008 | 20 | 0.100 |
Why?
|
| Psychiatry | 1 | 2014 | 129 | 0.100 |
Why?
|
| Mammography | 2 | 2022 | 272 | 0.100 |
Why?
|
| Confidentiality | 1 | 2012 | 52 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 496 | 0.090 |
Why?
|
| Drug Storage | 1 | 2011 | 21 | 0.090 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2002 | 86 | 0.090 |
Why?
|
| Poverty | 2 | 2010 | 286 | 0.090 |
Why?
|
| Forecasting | 1 | 2011 | 221 | 0.090 |
Why?
|
| Infant | 3 | 2011 | 1527 | 0.090 |
Why?
|
| Anemia, Sickle Cell | 1 | 2011 | 66 | 0.090 |
Why?
|
| Telephone | 1 | 2011 | 121 | 0.090 |
Why?
|
| Internet | 1 | 2014 | 458 | 0.090 |
Why?
|
| Seizures | 1 | 2011 | 118 | 0.090 |
Why?
|
| Medical Records | 2 | 2008 | 138 | 0.090 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 119 | 0.090 |
Why?
|
| Educational Status | 1 | 2011 | 271 | 0.080 |
Why?
|
| Reference Values | 1 | 2010 | 321 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2007 | 436 | 0.080 |
Why?
|
| Health Planning Guidelines | 1 | 2009 | 31 | 0.080 |
Why?
|
| Qualitative Research | 2 | 2012 | 612 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2007 | 576 | 0.080 |
Why?
|
| Medicare Part B | 2 | 2012 | 10 | 0.080 |
Why?
|
| Sampling Studies | 2 | 2012 | 66 | 0.080 |
Why?
|
| Medical Records, Problem-Oriented | 2 | 2021 | 13 | 0.080 |
Why?
|
| Antidepressive Agents | 2 | 2007 | 229 | 0.080 |
Why?
|
| Information Services | 1 | 2008 | 34 | 0.080 |
Why?
|
| Potassium | 2 | 2022 | 109 | 0.080 |
Why?
|
| Selection Bias | 2 | 2005 | 24 | 0.070 |
Why?
|
| Anticholesteremic Agents | 1 | 2008 | 34 | 0.070 |
Why?
|
| Anecdotes as Topic | 1 | 2007 | 10 | 0.070 |
Why?
|
| ROC Curve | 1 | 2008 | 259 | 0.070 |
Why?
|
| Costs and Cost Analysis | 1 | 2008 | 99 | 0.070 |
Why?
|
| Tartrates | 1 | 2007 | 1 | 0.070 |
Why?
|
| Atenolol | 1 | 2007 | 9 | 0.070 |
Why?
|
| Propanolamines | 1 | 2007 | 10 | 0.070 |
Why?
|
| Metoprolol | 1 | 2007 | 11 | 0.070 |
Why?
|
| Carbazoles | 1 | 2007 | 14 | 0.070 |
Why?
|
| Hospitals, Community | 1 | 2008 | 71 | 0.070 |
Why?
|
| Task Performance and Analysis | 1 | 2008 | 125 | 0.070 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2024 | 93 | 0.070 |
Why?
|
| Self Administration | 1 | 2007 | 47 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 220 | 0.070 |
Why?
|
| Needs Assessment | 2 | 2021 | 188 | 0.070 |
Why?
|
| Malpractice | 1 | 2006 | 17 | 0.070 |
Why?
|
| Medication Systems, Hospital | 1 | 2006 | 10 | 0.070 |
Why?
|
| Pulmonary Embolism | 1 | 2008 | 170 | 0.070 |
Why?
|
| Long QT Syndrome | 1 | 2006 | 28 | 0.070 |
Why?
|
| Ultrasonography, Doppler | 1 | 2006 | 24 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2006 | 27 | 0.070 |
Why?
|
| Educational Measurement | 1 | 2007 | 207 | 0.060 |
Why?
|
| Video Recording | 1 | 2006 | 126 | 0.060 |
Why?
|
| Observer Variation | 1 | 2006 | 201 | 0.060 |
Why?
|
| Health Status | 3 | 2017 | 449 | 0.060 |
Why?
|
| Hospital Information Systems | 1 | 2005 | 12 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2005 | 68 | 0.060 |
Why?
|
| Joints | 1 | 2005 | 30 | 0.060 |
Why?
|
| Muscular Diseases | 1 | 2005 | 45 | 0.060 |
Why?
|
| Arthritis | 1 | 2005 | 50 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 2 | 2016 | 96 | 0.060 |
Why?
|
| Geriatric Nursing | 1 | 2024 | 49 | 0.060 |
Why?
|
| Liability, Legal | 1 | 2004 | 16 | 0.060 |
Why?
|
| Depressive Disorder | 1 | 2007 | 293 | 0.060 |
Why?
|
| Vietnam | 1 | 2024 | 160 | 0.060 |
Why?
|
| Acute Disease | 3 | 2014 | 659 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2007 | 254 | 0.060 |
Why?
|
| Patient Care | 1 | 2004 | 78 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2006 | 471 | 0.060 |
Why?
|
| Wrist Injuries | 1 | 2003 | 14 | 0.060 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2023 | 4 | 0.050 |
Why?
|
| Resuscitation Orders | 1 | 2004 | 46 | 0.050 |
Why?
|
| Spinal Fractures | 1 | 2003 | 38 | 0.050 |
Why?
|
| Trust | 1 | 2004 | 68 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2006 | 522 | 0.050 |
Why?
|
| Liver Failure | 1 | 2003 | 16 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 387 | 0.050 |
Why?
|
| Health Surveys | 3 | 2013 | 306 | 0.050 |
Why?
|
| Medicare Part C | 1 | 2003 | 15 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2003 | 52 | 0.050 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2003 | 41 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2023 | 113 | 0.050 |
Why?
|
| Scotland | 1 | 2002 | 7 | 0.050 |
Why?
|
| Blood Coagulation | 1 | 2022 | 50 | 0.050 |
Why?
|
| Stomach Ulcer | 1 | 2002 | 7 | 0.050 |
Why?
|
| Duodenal Ulcer | 1 | 2002 | 4 | 0.050 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2003 | 167 | 0.050 |
Why?
|
| Alendronate | 1 | 2002 | 14 | 0.050 |
Why?
|
| Duodenal Diseases | 1 | 2002 | 17 | 0.050 |
Why?
|
| Intestinal Perforation | 1 | 2002 | 14 | 0.050 |
Why?
|
| Consumer Behavior | 1 | 2002 | 35 | 0.050 |
Why?
|
| Random Allocation | 1 | 2002 | 199 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 66 | 0.050 |
Why?
|
| Peptic Ulcer | 1 | 2002 | 21 | 0.050 |
Why?
|
| Prejudice | 1 | 2002 | 61 | 0.050 |
Why?
|
| Vision Disorders | 1 | 2022 | 59 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 233 | 0.050 |
Why?
|
| Attitude | 1 | 2002 | 100 | 0.050 |
Why?
|
| Peer Review, Research | 1 | 2002 | 46 | 0.050 |
Why?
|
| Health Resources | 1 | 2002 | 88 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2015 | 250 | 0.050 |
Why?
|
| Emotions | 1 | 2004 | 217 | 0.050 |
Why?
|
| Internal Medicine | 1 | 2002 | 148 | 0.050 |
Why?
|
| Health Behavior | 1 | 2005 | 473 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 194 | 0.050 |
Why?
|
| Coronary Artery Bypass | 1 | 2003 | 274 | 0.050 |
Why?
|
| Perception | 1 | 2022 | 179 | 0.050 |
Why?
|
| Electronics | 1 | 2021 | 37 | 0.050 |
Why?
|
| Reading | 1 | 2002 | 92 | 0.050 |
Why?
|
| Mass Screening | 2 | 2022 | 647 | 0.050 |
Why?
|
| Family Practice | 1 | 2002 | 204 | 0.040 |
Why?
|
| Income | 2 | 2013 | 160 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2002 | 553 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 282 | 0.040 |
Why?
|
| Transferrins | 1 | 2020 | 1 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 141 | 0.040 |
Why?
|
| Women's Health | 1 | 2003 | 390 | 0.040 |
Why?
|
| Ferritins | 1 | 2020 | 32 | 0.040 |
Why?
|
| Systole | 2 | 2014 | 109 | 0.040 |
Why?
|
| Canada | 2 | 2014 | 145 | 0.040 |
Why?
|
| Recurrence | 2 | 2014 | 578 | 0.040 |
Why?
|
| Transferrin | 1 | 2020 | 67 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2022 | 314 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 265 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2020 | 103 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2020 | 139 | 0.040 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2018 | 13 | 0.040 |
Why?
|
| Conservative Treatment | 1 | 2018 | 13 | 0.040 |
Why?
|
| Monitoring, Physiologic | 2 | 2013 | 150 | 0.040 |
Why?
|
| Competitive Medical Plans | 2 | 2009 | 4 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2006 | 726 | 0.040 |
Why?
|
| Liver | 1 | 2003 | 785 | 0.040 |
Why?
|
| Psychometrics | 2 | 2012 | 356 | 0.040 |
Why?
|
| Specialization | 1 | 2018 | 73 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 101 | 0.040 |
Why?
|
| Motivational Interviewing | 1 | 2018 | 42 | 0.040 |
Why?
|
| Risk-Taking | 1 | 2018 | 160 | 0.040 |
Why?
|
| Disease Progression | 1 | 2022 | 1044 | 0.040 |
Why?
|
| Journal Impact Factor | 1 | 2017 | 17 | 0.040 |
Why?
|
| Patient Preference | 1 | 2017 | 76 | 0.030 |
Why?
|
| Pregnancy | 1 | 2004 | 2355 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 1210 | 0.030 |
Why?
|
| Oxymorphone | 1 | 2016 | 6 | 0.030 |
Why?
|
| Echocardiography | 2 | 2014 | 459 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2016 | 27 | 0.030 |
Why?
|
| Rhabdomyolysis | 2 | 2007 | 26 | 0.030 |
Why?
|
| Tramadol | 1 | 2016 | 16 | 0.030 |
Why?
|
| Equipment Design | 1 | 2017 | 317 | 0.030 |
Why?
|
| Heart Rate | 1 | 2018 | 306 | 0.030 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2016 | 33 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 70 | 0.030 |
Why?
|
| Rhode Island | 1 | 2016 | 97 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2016 | 205 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2016 | 105 | 0.030 |
Why?
|
| California | 2 | 2007 | 160 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2015 | 115 | 0.030 |
Why?
|
| Gait | 1 | 2016 | 114 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2015 | 46 | 0.030 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 30 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2007 | 454 | 0.030 |
Why?
|
| Medicaid | 2 | 2009 | 335 | 0.030 |
Why?
|
| Economic Recession | 1 | 2014 | 5 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 249 | 0.030 |
Why?
|
| Echocardiography, Stress | 1 | 2014 | 13 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2014 | 77 | 0.030 |
Why?
|
| Analgesics | 1 | 2015 | 100 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 314 | 0.030 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2013 | 2 | 0.030 |
Why?
|
| Creatinine | 1 | 2013 | 123 | 0.030 |
Why?
|
| Proteinuria | 1 | 2013 | 37 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 82 | 0.030 |
Why?
|
| Buprenorphine | 1 | 2016 | 186 | 0.030 |
Why?
|
| Health Facility Administrators | 1 | 2012 | 7 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 340 | 0.030 |
Why?
|
| Global Health | 1 | 2014 | 163 | 0.030 |
Why?
|
| Etanercept | 1 | 2012 | 31 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 61 | 0.030 |
Why?
|
| Adalimumab | 1 | 2012 | 36 | 0.020 |
Why?
|
| Infliximab | 1 | 2012 | 55 | 0.020 |
Why?
|
| Health Services Misuse | 1 | 2012 | 19 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2011 | 45 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2006 | 1311 | 0.020 |
Why?
|
| Angioedema | 1 | 2011 | 10 | 0.020 |
Why?
|
| Hypotension, Orthostatic | 1 | 2011 | 26 | 0.020 |
Why?
|
| Cost Savings | 1 | 2011 | 56 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 1023 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 220 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 452 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 172 | 0.020 |
Why?
|
| Health Care Sector | 1 | 2009 | 20 | 0.020 |
Why?
|
| Hospital Units | 1 | 2008 | 8 | 0.020 |
Why?
|
| Time | 1 | 2008 | 27 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2013 | 403 | 0.020 |
Why?
|
| Efficiency | 1 | 2008 | 41 | 0.020 |
Why?
|
| Safety | 1 | 2008 | 141 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2008 | 102 | 0.020 |
Why?
|
| Naproxen | 1 | 2007 | 7 | 0.020 |
Why?
|
| Celecoxib | 1 | 2007 | 14 | 0.020 |
Why?
|
| Lactones | 1 | 2007 | 25 | 0.020 |
Why?
|
| Sulfones | 1 | 2007 | 37 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 873 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2007 | 7 | 0.020 |
Why?
|
| Aluminum | 1 | 2007 | 14 | 0.020 |
Why?
|
| Program Development | 1 | 2008 | 210 | 0.020 |
Why?
|
| Cost Sharing | 1 | 2007 | 14 | 0.020 |
Why?
|
| New Jersey | 1 | 2007 | 26 | 0.020 |
Why?
|
| Pyridines | 1 | 2007 | 98 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2007 | 74 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2007 | 123 | 0.020 |
Why?
|
| New York | 1 | 2007 | 137 | 0.020 |
Why?
|
| Torsades de Pointes | 1 | 2006 | 5 | 0.020 |
Why?
|
| Amitriptyline | 1 | 2006 | 8 | 0.020 |
Why?
|
| Informed Consent | 1 | 2007 | 133 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2006 | 90 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2005 | 44 | 0.020 |
Why?
|
| Half-Life | 1 | 2004 | 70 | 0.010 |
Why?
|
| Self Concept | 1 | 2005 | 104 | 0.010 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2004 | 35 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 2004 | 95 | 0.010 |
Why?
|
| Resuscitation | 1 | 2004 | 69 | 0.010 |
Why?
|
| Chromans | 1 | 2003 | 16 | 0.010 |
Why?
|
| Sulfonylurea Compounds | 1 | 2003 | 14 | 0.010 |
Why?
|
| Thiazoles | 1 | 2003 | 47 | 0.010 |
Why?
|
| Prenatal Care | 1 | 2004 | 180 | 0.010 |
Why?
|
| Metformin | 1 | 2003 | 67 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 900 | 0.010 |
Why?
|
| Exercise Test | 1 | 2003 | 234 | 0.010 |
Why?
|
| Fibrinolytic Agents | 1 | 2003 | 165 | 0.010 |
Why?
|
| Aspirin | 1 | 2003 | 186 | 0.010 |
Why?
|
| Physician's Role | 1 | 2002 | 119 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 724 | 0.010 |
Why?
|
| Insulin | 1 | 2003 | 687 | 0.010 |
Why?
|